Form 10-Q CONCERT PHARMACEUTICALS, For: Jun 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Roth Keeps Concert Pharma (CNCE) at Buy; Making Good Progress with Clinical Programs
August 12, 2014 3:23 PM EDTRoth Capital affirms Concert Pharmaceuticals (Nasdaq: CNCE) at Buy with a target price of $28 following the company's Q2 results.
Concert reported Q2 loss of $0.45 per share versus Roth's estimated loss of $0.47 per share.
Analyst Joseph Pantginis commented, We believe Concert is making good progress on their clinical programs, both in their in-house and partnered programs. The company's R&D expenses are... More
Concert Pharmaceuticals, Inc. (CNCE) Misses Q2 EPS by 3c
August 12, 2014 9:28 AM EDTConcert Pharmaceuticals, Inc. (NASDAQ: CNCE) reported Q2 EPS of ($0.45), $0.03 worse than the analyst estimate of ($0.42). Revenue for the quarter came in at $1.2 million versus the consensus estimate of $1.3 million.
The clinical and regulatory successes we have realized in the recent months are... More
